ERBB2 and cancer: We found no significant correlation between ATOX1 mRNA levels and patient survival for Basal-like (79 vs. 76 months), Claudin low (110 vs. 105 months) and HER2-enriched cancer subtypes (106 vs. 82 months) [Fig. 2, Fig. S4 shows overall survival (OS) KM plots].